Table 1 Open in new tab Demographics of...

Reference

Type of study

Diagnosis

TMP/SMX,
no. of patients (%)

Controls,
no. of patients (%)

TMP/SMX,
median age (IQR)/
no. of females (%)

Controls,
median age (IQR)/
no. of females (%)

Stegeman et al. [5]

RCT

Systemic/generalized GPA

(50.6)

(49.4)

56 (21–82)/

11 (26.8)

57 (25–83)/

12 (30.0)

Zycinska et al. [8]

RCT

Systemic/generalized GPA

(51.6)

(48.4)

46.1 (21.1–56.5)/

8 (50.0)

51.4 (28.4–76.0)/

8 (53.3)

Reinhold-Keller et al. [9]

Prospective cohort study

Systemic/generalized GPA

Group 1^a:

initial phase GPA: 19/72 (26.4)

Group 2^b:

TMP/SMX: 24/53 (45.3)

; TMP/SMX + GC: 8/53 (15.1)

Group 1^a:

generalized GPA: 53/72

(73.6)

Group 2^b:

no therapy: 21/53

(39.6)

Group 1^a:

initial phase GPA: 41 (23–67)/

14 (73.7)

Group 2^b:

TMP/SMX: 48 (17–73)/

14 (59.3);

TMP/SMX + GC: 46.5 (21–63)/5 (62.5)

Group 1^a:

generalized

GPA: NS

Group 2^b:

no therapy: 37 (12–70)/

9 (42.9)

de Groot et al. [10]

Prospective cohort study

Systemic/generalized GPA

Group B:

TMP/SMX: 24 (36.9)

Group D:

TMP/SMX + GC: 8 (12.3)

Group A:

MTX: 22 (33.8)

Group C:

MTX + GC: 11 (16.9)

Group B:

TMP/SMX: 48 (17–73)/

14 (58.3)

Group D:

TMP/SMX + GC: 46.5 (21–63)/

5 (62.5)

Group A:

MTX: 48 (12–60)/

6 (27.3)

Group C:

MTX + GC: 45 (31–67)/

7 (63.6)

Holle et al. [11]

Prospective cohort study

Limited ENT GPA

(52.0)

(48.0)

Salmela et al. [4]

Prospective analysis of two RCTs

Systemic/generalized GPA, MPA

(27.5)

145

(72.5)

NS (no differences)

Yegin et al. [12]

Retrospective cohort study

Systemic/generalized GPA

12 (75)

4 (25)

NS [mean (s.d.) total population: 51.6 (11.9)]/NS [total population: 6 (28%)]

Table 1

Open in new tab

Demographics of patients included in studies assessing the role of TMP/SMX to prevent relapses

Reference	Type of study	Diagnosis	TMP/SMX, no. of patients (%)	Controls, no. of patients (%)	TMP/SMX, median age (IQR)/ no. of females (%)	Controls, median age (IQR)/ no. of females (%)
Stegeman et al. [5]	RCT	Systemic/generalized GPA	41 (50.6)	40 (49.4)	56 (21–82)/ 11 (26.8)	57 (25–83)/ 12 (30.0)
Zycinska et al. [8]	RCT	Systemic/generalized GPA	16 (51.6)	15 (48.4)	46.1 (21.1–56.5)/ 8 (50.0)	51.4 (28.4–76.0)/ 8 (53.3)
Reinhold-Keller et al. [9]	Prospective cohort study	Systemic/generalized GPA	Group 1^a: initial phase GPA: 19/72 (26.4) Group 2^b: TMP/SMX: 24/53 (45.3) ; TMP/SMX + GC: 8/53 (15.1)	Group 1^a: generalized GPA: 53/72 (73.6) Group 2^b: no therapy: 21/53 (39.6)	Group 1^a: initial phase GPA: 41 (23–67)/ 14 (73.7) Group 2^b: TMP/SMX: 48 (17–73)/ 14 (59.3); TMP/SMX + GC: 46.5 (21–63)/5 (62.5)	Group 1^a: generalized GPA: NS Group 2^b: no therapy: 37 (12–70)/ 9 (42.9)
de Groot et al. [10]	Prospective cohort study	Systemic/generalized GPA	Group B: TMP/SMX: 24 (36.9) Group D: TMP/SMX + GC: 8 (12.3)	Group A: MTX: 22 (33.8) Group C: MTX + GC: 11 (16.9)	Group B: TMP/SMX: 48 (17–73)/ 14 (58.3) Group D: TMP/SMX + GC: 46.5 (21–63)/ 5 (62.5)	Group A: MTX: 48 (12–60)/ 6 (27.3) Group C: MTX + GC: 45 (31–67)/ 7 (63.6)
Holle et al. [11]	Prospective cohort study	Limited ENT GPA	26 (52.0)	24 (48.0)	NS	NS
Salmela et al. [4]	Prospective analysis of two RCTs	Systemic/generalized GPA, MPA	55 (27.5)	145 (72.5)	NS (no differences)	NS (no differences)
Yegin et al. [12]	Retrospective cohort study	Systemic/generalized GPA	12 (75)	4 (25)	NS [mean (s.d.) total population: 51.6 (11.9)]/NS [total population: 6 (28%)]	NS [mean (s.d.) total population: 51.6 (11.9)]/NS [total population: 6 (28%)]

Reference	Type of study	Diagnosis	TMP/SMX, no. of patients (%)	Controls, no. of patients (%)	TMP/SMX, median age (IQR)/ no. of females (%)	Controls, median age (IQR)/ no. of females (%)
Stegeman et al. [5]	RCT	Systemic/generalized GPA	41 (50.6)	40 (49.4)	56 (21–82)/ 11 (26.8)	57 (25–83)/ 12 (30.0)
Zycinska et al. [8]	RCT	Systemic/generalized GPA	16 (51.6)	15 (48.4)	46.1 (21.1–56.5)/ 8 (50.0)	51.4 (28.4–76.0)/ 8 (53.3)
Reinhold-Keller et al. [9]	Prospective cohort study	Systemic/generalized GPA	Group 1^a: initial phase GPA: 19/72 (26.4) Group 2^b: TMP/SMX: 24/53 (45.3) ; TMP/SMX + GC: 8/53 (15.1)	Group 1^a: generalized GPA: 53/72 (73.6) Group 2^b: no therapy: 21/53 (39.6)	Group 1^a: initial phase GPA: 41 (23–67)/ 14 (73.7) Group 2^b: TMP/SMX: 48 (17–73)/ 14 (59.3); TMP/SMX + GC: 46.5 (21–63)/5 (62.5)	Group 1^a: generalized GPA: NS Group 2^b: no therapy: 37 (12–70)/ 9 (42.9)
de Groot et al. [10]	Prospective cohort study	Systemic/generalized GPA	Group B: TMP/SMX: 24 (36.9) Group D: TMP/SMX + GC: 8 (12.3)	Group A: MTX: 22 (33.8) Group C: MTX + GC: 11 (16.9)	Group B: TMP/SMX: 48 (17–73)/ 14 (58.3) Group D: TMP/SMX + GC: 46.5 (21–63)/ 5 (62.5)	Group A: MTX: 48 (12–60)/ 6 (27.3) Group C: MTX + GC: 45 (31–67)/ 7 (63.6)
Holle et al. [11]	Prospective cohort study	Limited ENT GPA	26 (52.0)	24 (48.0)	NS	NS
Salmela et al. [4]	Prospective analysis of two RCTs	Systemic/generalized GPA, MPA	55 (27.5)	145 (72.5)	NS (no differences)	NS (no differences)
Yegin et al. [12]	Retrospective cohort study	Systemic/generalized GPA	12 (75)	4 (25)	NS [mean (s.d.) total population: 51.6 (11.9)]/NS [total population: 6 (28%)]	NS [mean (s.d.) total population: 51.6 (11.9)]/NS [total population: 6 (28%)]

Initial phase GPA: symptoms restricted to the upper and/or lower airways without constitutional symptoms or systemic vasculitis (limited GPA).

Group 1: induction therapy in initial phase/limited GPA.

Group 2: maintenance of remission in generalized GPA. GC: glucocorticoid; GPA: granulomatosis with polyangiitis; IQR: interquartile range; MPA: microscopic polyangiitis; NS: not specified; RCT: randomized controlled trial; TMP/SMX: trimethoprim/sulfametoxazole.

This Feature Is Available To Subscribers Only